New anticoagulants for the treatment of venous thromboembolism

Minerva Medica

Volumn 104, Issue 2, 2013, Pages 131-139

  Prandoni, P ^a   Dalla Valle, F ^a   Piovella, C ^a   Tormene, D ^a   Pesavento, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Apixaban; Dabigatran etexilate; Rivaroxaban; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; APIXABAN; ARGATROBAN; ATECEGATRAN METOXIL; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; EDOXABAN; ENOXAPARIN; HEPARIN; HIRULOG; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT HIRUDIN; RIVAROXABAN; SERINE PROTEINASE; SOFIGATRAN; THROMBIN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HEART INFARCTION; HIP ARTHROPLASTY; HUMAN; KIDNEY FAILURE; KNEE ARTHROPLASTY; LIVER FUNCTION TEST; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; REVIEW; SIDE EFFECT; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BIOTIN; HUMANS; OLIGOSACCHARIDES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84877315197     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al. Antithrombotic therapy for VTE disease: American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141(2 Suppl):e419-94S.
2. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106. (Pubitemid 40720733)
3. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66.
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older americans. N Engl J Med 2011;365:2002-12.
5. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005;3:939-42. (Pubitemid 41632823)
6. Chitsike RS, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012;10:2039-44.
7. Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol 2012;88:185-94.
8. Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD et al. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol 2010;9:41-8.
9. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis 2008;25:52-60.
10. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. (Pubitemid 41262337)
11. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:234-56.
12. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009;48:1-22.
13. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
14. Schulman S, Kakkar AK, Schellong SM. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Proc ASH. Blood 2011;118 (Suppl. 21):abstract 205.
15. Schulman S, Baanstra D, Eriksson H. Dabigatran versus placebo for extended manteinance therapy of venous thromboembolism. J Thromb Haemost 2011;9(s2):037.
16. Schulman S, Eriksson H, Goldhaber SZ. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9(s2):731.
17. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012 [Epub ahead of print].
18. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21. (Pubitemid 41393676)
19. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80. (Pubitemid 41803696)
20. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban - an oral, direct Factor Xa inhibitor - in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos 2009;37:1046-55.
21. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009;37:1056-64.
22. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65.
23. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD et al. ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116:180-7. (Pubitemid 47057524)
24. Büller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS et al. Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 2008;112:2242-7.
25. The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
26. The Einstein Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
27. Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: Selection of phase III trial dose. Clin Pharmacol Ther 2010;88:375-82.
28. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 2010;104:302-10.
29. Carreiro J, Ansell J. Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008;17:1937-45.
30. Büller HR, Deichman D, Prins M. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for the symptomatic deep vein thrombosis. The Botticelli DVT dose ranging study. J Thromb Haemost 2008;6:1313-8. (Pubitemid 352016310)
31. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102:811-5.
32. Paty I, Trellu M, Destors JM, Cortez P, Boelle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-9.
33. The Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011;9:92-9.
34. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-9.